General Information
Version
6.3
Revision date
2023-11-26
Product name
Sodium deuteroxide
REACH No
This
1.2.2. Uses advised against
For R&D use only. Not for pharmaceutical, household or other uses
Emergency telephone
+(45)-6991 8573, +(45)-8212 1212
Icons in SDS
Company Information
company name
Merck Life Science ApS
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H314
Hazard statements
Code
Statements
H314
Causes severe skin burns and eye damage
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H314 Causes severe skin burns and eye damage.
Precautionary statements
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 Immediately call a POISON CENTER/ doctor.
Supplemental label elements
none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Skin corrosion (Category 1A), H314 For the full text of the H-Statements mentioned in this Section, see Section 16.
